Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't understand who would be selling at these prices?? There are too many good things going on here.
Great News Today!
Stellar Pharmaceuticals Allowed Uracyst(R) Patent in United States of America
Buzz up! 0
Print
Companies:STELLAR PHAMACEUTICL
Related Quotes
Symbol Price Change
SLXCF.OB 0.87 0.00
Press Release Source: Stellar Pharmaceuticals Inc. On Wednesday June 23, 2010, 7:00 am EDT
LONDON, ONTARIO--(Marketwire - 06/23/10) - Stellar Pharmaceuticals Inc. (OTC.BB:SLXCF - News) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property central to one of the Company's lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%), which is useful in the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS").
Stellar's patent application, entitled "Cystitis Treatment with High Dose Chondroitin Sulfate," describes the treatment of IC/PBS by instillation of an optimized dose of chondroitin sulfate. Upon Stellar completing the final formalities, including the payment of applicable fees, the Company expects this patent to issue. Once issued, the patent will expire in 2024.
Peter Riehl, Stellar's President and Chief Executive Officer, commented, "With Uracyst® patents already issued in USA, Canada, China, and Australia, and with numerous additional international patents pending, the USA patent expands Stellar's already formidable intellectual property estate. Issuance of this patent also triggers a milestone payment of US$1,300,000 from our USA based marketing and distribution partner, Watson Pharma, Inc. We are very excited about the future potential of Uracyst® in this important market, which is currently in clinical development in the USA. This Notice of Allowance further validates the innovative nature of Stellar's approach to the treatment of interstitial cystitis/painful bladder syndrome, and underscores our Company's leadership in this field."
About Uracyst®
It is believed that over 70% of IC/PBS patients have defects in their bladder glycosaminoglycan layers. The glycosaminoglycan ("GAG") layer is a mucosal lining of the bladder that acts as a protective barrier against irritants and toxins in the urine and defends against bacterial adherence. When the GAG layer is damaged, these irritants and toxins in the urine seep through, causing an irritation to the bladder wall. This results in increased frequency and urgency to void (up to 60 times a day). Many IC/PBS patients also experience severe pelvic pain. These symptoms can be debilitating and have a serious impact on a patient's quality of life.
Chondroitin sulfate (ChS) is believed to be the major GAG component responsible for the barrier function. Uracyst® was developed to replenish this defect in IC/PBS patients.
Uracyst® 2% (400 mg) ChS dose has been shown to be the ideal dosage to saturate the bladder, thus restoring the barrier function. Instilled fluid volume of Uracyst® 20 mL also allows patients to retain the treatment in the bladder for a longer period of time, enabling a better uptake of the delivered dosage and a faster onset of symptomatic relief. Uracyst® is also one of the most cost effective treatments for these patients. Combine treatment efficacy with the most cost effective therapy and it becomes understandable why Uracyst® is becoming the product of choice in treating IC/PBS.
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Both NeoVisc and Uracyst have their CE Mark certification for the European Community. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
Hey Glasses can you smell what's cookin?? Is today the day all us longs have been waiting for?? Lets have a great day Qasp.
Who's shorting this stock?? They keep walking it down on such little volume. Are we ever going to get that pr that Dutchess is paid in full?
There's some really good accumulation going on here.
Thats right brother. This is going to be a awesome ride. Lets buckle in. At the end we can go and celebrate. Blast off....
A non believer. Believe in Qasp and you shall be rewarded.
Thanks for being frank. As always you always do a great job of explaining.
Hey Banker my friend glasses wants to you if your flipping those shares you bought a few mths back. You told us all you will keep your core holdings, but you also own some for flipping??
2mil trade way under bid. BB maybe??? jmo
Good to see people are sticking it out here. This is a great story stock. Just needs time to develop. Tiny float and outstanding. I tried to find out about the China approval as well. I was told that they could not give me a time table on the approval due to non disclosure issues.
Db7 you still in this, or you traded out?
Hey Grapejuice are you out of here??
OLMP is finally off the ask. Maybe now we can finally move higher.
Where did everyone go??
I'm still in it. Haven't sold a share. From what I gather we should be hearing soon from china. Once that occurs watch out. I wouldn't be looking for a trade here. JMO
Common glasses hit one out of the park. You the man.... :)
1st q results out. Doesn't look too good. Basically a break even with revs down. Not good for us longs.
Turned out to be an good day. Very good volume. Extremely encouraging action today.
Ferris said in his conference call earnings out before 15. Doesn't that mean today, not monday???
Ok thanks for that.
Does anyone know when 1st Q numbers will be released??
TIMBER!! The first Q earnings weren't that bad. This is a solid stock with a great future.
That explains it all. You probably don't even own one share. Lonely eyeglass salesman. Go Qasp...
Hey our bookmarks are going higher. We are getting some news eyes on our little hidden gem....
nice post glasses. your a big fan of qasp?
Did you get a response from the company? There IR guy usually responds fairly quickly.
Did you get a response from the company? There IR guy usually responds fairly quickly.
Nothing surprises me anymore about this stock. Its quite likely it could go back down and test the dollar level, but we all have seen how its been rising nice and steady.I'm not selling a share here. I've been patiently holding for a long time, I feel our time is near to be handsomely rewarded.
You have to remember 2 things. We have Watsons trial concluding I believe in the 2-3rd Q and we have the approval for China coming soon as well. Could change things real fast. JMO
You may get your wish if the stock keeps these stream of good news coming. Nice action today.
Nice mention.
Cowen ups Watson to outperform; Stellar’s Uracyst high in rationale
May 7, 2010 by leonardzehr · Leave a Comment
Cowen & Co. upgraded Watson Pharmaceuticals (NYSE:WPI) to “outperform” from “neutral,” saying it has “significantly underappreciated its brand pipeline” and making an earlier reference to the potential of Stellar Pharmaceuticals’ (OTCBB: SLXCF (SLXCF 1.15 ?0.00%)) Uracyst drug for painful interstitial cystitis/painful bladder syndrome.
Analyst Ken Cacciatore writes that Uracyst, which is sold in Canada by Stellar and in Europe by multiple commercial partners, “looks very promising.” Watson licensed Uracyst for the U.S. market in 2006.
He figures the drug has a peak sales potential of $200 million (U.S.), assuming a U.S. patient population of about two million, with about 50% diagnosed and treated, and peak penetration within that treated population of 35%, using seven-to-10 vials per patient annually at a $75 wholesale price per vial.
Watson’s pivotal clinical study, which started in July, 2009, should conclude by the end of 2010. Mr. Cacciatore expects that Watson will file for marketing approval with the FDA next year, with a decision likely by mid-2012.
Part 2
Re: URACRYST SALES PROJECTION 7-May-10 12:42 pm
PART 2-There is not a stock out here in this niche that has the same profile that Stellar has and it is one of the most undervalued plays in my port...which is why i keep adding...some today even. If you don't own it I would at least do the R&D as I think that among all the stocks in my ports this is the best portfolio maker of all. This one year chart says it better than I ever could--then a para from the WPI write up by Cohen---->only 23m shares out---another big plus---->
http://bigcharts.marketwatch.com/quickch...
=============================================
FROM COHEN AND CO WPI RECCOMENDATION-
Uracyst Could Have Peak Sales Of $200MM
In recent years, scientists have started to use the terms bladder pain syndrome
(BPS) or painful bladder syndrome (PBS) to describe cases with painful urinary
symptoms that may not meet the strictest definition of IC. Medical literature
estimates that about 1-2MM Americans have IC/PBS and a majority of these
patients are women. Assuming U.S. patient population of about 2MM, about 50%
diagnosed and treated, peak penetration within that treated population of 35%,
seven-to-ten vials per patient annually, and $75 wholesale price per vial, Uracyst
could be approximately $200MM in peak potential. These estimates are in line
with Elmiron?s current annual sales, which as noted earlier were roughly
$170MM and on approximately 500,000 prescriptions in 2009.
Cowen Report
URACRYST SALES PROJECTION 7-May-10 12:41 pm
PART 1-LXCF.OB...Cohen just completed a write up on Watson Pharma with a rec to outperform. Part of that write up, and supporting the projected numbers, includes Uracryst. Cohen devotes 5 or 6 paragraphs to Uracryst and here is the meat (below) of the matter--pls keep in mind that Stellar posted sales of $3m vs $2m in last qtr and that rev growth of 39% was due in large part to Uracryst sales which are already occurring in a number of countries and more countries have been licensed since the end of last qtr. Most spectacular of all for a $1 drug/bio/medical stock is that they had positive net inc of $238,000 (would have been more except for $163,000 in non cash stock options and amortization expenses)....these numbers alone---rapidly rising revenues and net inc plus 3rd year in a row of cash positive operations--warrant a price of $3-$4.00 when factoring in rapid positive growth of all ratios. When you add Watson's agreement with Stellar to the mix which includes approx $7.5m more in milestones to be paid to Stellar as certain points are met along the way and then the FDA approval of Uracryst (has already been approved in many countries incl Canada and I think UK plus others--chances of Watson not getting final approval are to me nil) then the whole ballgame changes ref the numbers. Cohen estimates $200m in peak annual sales...that is them talking, not me. Do you have any idea what that will do to this stock price once in gear?? Pick a number--$15-$20??? I have no problem with saying that assuming Cohen's est is in the ballgame and they should know.
The problem with these guys is they don't know how to spread the word about themselves. Revenues are strong, they have cash in the bank for operations, so no need to dilute. There waiting for Watson and china to come on board. Lots of good things going on here. Just need to get the word out. JMO
Thats for sure!! Small float and tiny outstanding. This is a little undiscovered gem.
MORE GOOD NEWS THIS MORNING. Lets get this puppy rolling.
Stellar Pharmaceuticals Inc. Signs Agreement for Distribution and Sale of Uracyst(R) in Germany and Austria
Continued Expansion of Stellar's Global Strategy
Buzz up! 0
Print
Companies:STELLAR PHAMACEUTICL
Related Quotes
Symbol Price Change
SLXCF.OB 1.12 +0.02
Press Release Source: Stellar Pharmaceuticals Inc. On Thursday May 6, 2010, 7:30 am EDT
LONDON, ONTARIO--(Marketwire - 05/06/10) - Stellar Pharmaceuticals Inc. ("Stellar") (OTC.BB:SLXCF - News), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing an license agreement with medac GmbH ("medac") for the distribution and sale of one of its lead products, Uracyst® (a sterile sodium chondrotin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS") in Germany and Austria.
Uracyst® is trademarked as Uropol® in Germany and Austria. With the approved CE mark for the product already in place, it is expected that medac will launch Uropol® in the third quarter of 2010. Under the terms of the agreement, medac will pay Stellar an upfront licensee fee in addition to a specified transfer price in exchange for the rights to an exclusive agreement for this territory. The agreement has an initial five-year term with additional two-year renewal periods.
"We are pleased to enter into this relationship with medac, a company that has a strong presence in the urology markets in Germany and Austria. We are confident that, with medac's support, Uracyst®/Uropol® will gain significant awareness, acceptance and adoption in these jurisdictions," said Peter Riehl, Stellar's President and Chief Executive Officer.
Mr. Riehl continued, "Germany is the single largest market in the European Community. Accordingly, this agreement not only represents an important revenue opportunity for Stellar and medac, but also offers hope for the first time to the thousands of German residents who are currently suffering from IC/PBS."
ABOUT medac GmbH
medac is a privately owned German-based, globally represented pharmaceutical company, specializing particularly in the fields of oncology and urology. medac develops and markets highly specialized pharmaceutical products and occupies a leading position in the field of Uro oncology. Their portfolio includes approximately 40 products approved in 70 countries worldwide with an annual turnover of more than 230 million Euros.
For more information on medac visit www.medac.de/medac_international/relaunch/index.php.
About Uracyst®
Interstitial Cystitis and Painful Bladder Syndrome are inflammatory diseases of the bladder wall, which cause pain, discomfort and frequent urination for those afflicted. There is no known cure for IC/PBS and currently approved products attempt to alleviate the symptoms of the disease. The quality of life for patients with IC/PBS is extremely poor, as they may need to void up to 60 times per day. Uracyst®, a sodium chondroitin sulfate solution, supplements and replenishes deficiencies in the glycosaminoglycan (GAG) lining of the bladder. The GAG lining acts as a protective barrier against irritants and toxins in the urine, and defends against bacterial adherence. Many researchers believe that more than 70% of patients with IC/PBS have deficient GAG layers allowing irritants and toxins in the urine to seep through this protective barrier causing an inflammation of the bladder wall.
Stellar currently markets Uracyst® directly in Canada and through license agreements in Denmark, Sweden, Norway, Finland, Iceland, the UK, Republic of Ireland, Netherlands, Italy, Turkey and now Portugal. Stellar also has out licensing agreements in place for Uracyst® in Israel, United States and China, territories which are each currently awaiting regulatory approvals.
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
Contact:
Contacts:
Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(800) 639-0643 or (519) 434-1540
medac GmbH
Nickolaus Stolberg
Managing Director
+49 (4103) 8006 547
Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
(416) 587-3200
www.stellarpharma.com
Investor Contact
Kilmer Lucas Inc.
Stephen Kilmer, President
(905) 690-2400 ext. 21
stephen@kilmerlucas.com
Buzz up! 0
SendSharePrint
Related Headlines
Stellar Pharmaceuticals Inc. Signs Agreement for Distribution and Sale of Uracyst(R) in Germany and Austria - Marketwire
STELLAR PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits - EDGAR Online
Stellar Pharmaceuticals Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Portugal - Marketwire
STELLAR PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E - EDGAR Online
Stellar Pharmaceuticals Announces Steven H. Goldman Rejoins Board of Directors - Marketwire
Related Message Boards
STELLAR PHAMACEUTICL
Sponsored Links
7,500% Profit From Penny Stocks?
Money Making Email Alerts. Huge Gains in Days. Sign Up Now for FREE.
www.KillerPennyStocks.com
investment market stock strategy
Pick hot stocks, receive stock alerts & investment info instantly.
www.stocktwiter.com
Buy Stocks for $4
No Account or Investment Minimums. No Inactivity Fees. Start Today.
www.ShareBuilder.com
finance investing stock market
Trade stocks with optionsXpress. Free tools to help with your trade
optionsXpress.com
Top Stories
Wall Street Wobbles in Early Trade; European Debt Still Weighs - AP
Retailers report more modest April shopping - AP
ECB did not discuss buying government bonds - AP
BP: Oil leak will be stopped, but can't say when - AP
ADVERTISEMENT
Tech Ticker Recent Posts
Jim Rogers Is Now Shorting A Major Western Financial Firm That Everyone Thinks Is Sound - Vincent Fernando, CFA
Xerox CEO: Health-Care Reform Helping, But Business "a Long Way from Really Good" - Peter Gorenstein
Big Job Cuts Mean Short-Term Gain, Long-Term Pain for Shareholders, Study Finds - Heesun Wee
View More
Subscribe to Topics
Top Stories
Add Alert
SLXCF.OB Headlines
Add Alert
See all RSS links
ADVERTISEMENT
News Out this Morning!!
Stellar Pharmaceuticals Signs Licensing Agreement for Distribution and Sale of Uracyst(R) in Portugal
Company Continues Expansion of Global Out-Licensing Program
Buzz up! 0
Print
Companies:STELLAR PHAMACEUTICL
Related Quotes
Symbol Price Change
SLXCF.OB 1.10 +0.04
Press Release Source: Stellar Pharmaceuticals Inc. On Wednesday May 5, 2010, 11:42 am EDT
LONDON, ONTARIO--(Marketwire - 05/05/10) - Stellar Pharmaceuticals Inc. ("Stellar") (OTC.BB:SLXCF - News), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing a licensing agreement for the distribution and sale of one of its lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS"), in Portugal with CPH Companhia Portuguesa Higiene ("CPH").
CPH is a specialty pharmaceutical sales and marketing company based in Alcabideche, Portugal. One of CPH's major focus areas is urology, the primary target market for Uracyst®.
With the CE mark for Uracyst® already in place, it is expected that Uracyst will be launched by CPH in the second quarter of 2010. Under the terms of the agreement, CPH will pay Stellar an upfront licensee fee in addition to a specified transfer price in exchange for the rights to an exclusive license for this territory. This agreement has an initial five-year term and may be renewed for an additional three-year term with the mutual agreement of both parties.
Peter Riehl, Stellar's President and Chief Executive Officer, stated, "Expanding the global licensing of Uracyst® is a major growth driver for Stellar. Accordingly, the signing of this agreement, which will add to the number of European territories where Uracyst® is commercially available, is a key milestone achievement for our Company. We look forward to building a successful long-term working relationship with CPH."
About CPH Companhia
CPH is a centennial Portuguese pharmaceutical company founded in 1891 and integrated since 2008 in the Ferrer Group, a multinational Spanish company. CPH has a tradition in the CNS, Urology, Cardiovascular and, recently, in the Oncology OTC fields.
About Uracyst®
It is believed that over 70% of IC/PBS patients have defects in their bladder glycosaminoglycan layers. The glycosaminoglycan ("GAG") is a mucosa lining of the bladder that acts as a protective barrier against irritants and toxins in the urine and defends against bacterial adherence. When the GAG is damaged, these irritants and toxins in the urine seep through, causing an irritation to the bladder wall. This results in increased frequency and urgency to void (up to 60 times a day). Many IC/PBS patients also experience severe pelvic pain. These symptoms can be debilitating and have a serious impact on a patients quality of life.
Chondroitin sulfate (ChS) is believed to be the major proteoglycan responsible for the GAG barrier function. Uracyst® was developed to replenish this defect. Uracyst® 2% (400 mg) ChS dose has been shown to be the ideal dosage to saturate the bladder, thus restoring the barrier function. Instilled fluid volume of Uracyst® 20 mL also allows patients to retain the treatment in the bladder for a longer period of time thus a better uptake of the delivered dosage and a faster onset of symptomatic relief. Uracyst® is also one of the most cost effective treatments for these patients. Combine treatment efficacy with the most cost effective therapy and it becomes understandable why Uracyst® is becoming the product of choice in treating IC/PBS.
Press Release - CPH Companhia
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Both NeoVisc and Uracyst have their CE Mark certification for the European Community. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
Contact:
Contacts:
Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(800) 639-0643 or (519) 434-1540
Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
(416) 587-3200
CPH Pharma
Armando Mota
Commercial Director
(351) 919938231
armando.mota@cph.pt
Investor Contact:
Kilmer Lucas Inc.
Stephen Kilmer, President
(905) 690-2400 ext. 21
stephen@kilmerlucas.com
Buzz up! 0
SendSharePrint
I've been holding for a while myself. We need something besides Dutchess to talk about for tomorrow. I don't think we will hear any earth shattering news myself. Hope I'm wrong. JMO
Any volume here is good volume. There has been such limited trading action here for the longest. There is such a tight float here. Anything possitive and this could rocket. JMO